Medicus Pharma Moves to Regain Nasdaq Compliance with 50-to-1 Reverse Split
MDCX is trading near its 52-week low of $0.144 (11% above the low) on light trading volume (0.1× avg).
Summary
Medicus Pharma will execute a 50-to-1 reverse stock split on October 12, 2026, to regain Nasdaq's minimum bid price compliance. The move follows months of delisting pressure and a going concern warning.
Key Events · Corporate Governance and Compliance · MDCX
-
50-to-1 Reverse Split Approved
The board approved a 50-to-1 consolidation effective October 12, 2026, to increase the bid price and regain Nasdaq compliance.
-
Nasdaq Delisting Pressure
Delisting threats have loomed since April 2026, and the company recently reiterated going concern doubts with $15.2 million in cash.
-
Fractional Share Treatment
No fractional shares will be issued; shareholders with uneven holdings will be rounded down and paid cash in lieu.
-
Warrant and Option Adjustments
Outstanding warrants, options, and convertible securities will be proportionately adjusted for exercise price and share count.
Analysis · MDCX · Life Sciences
To lift the bid price above Nasdaq's $1.00 minimum and avoid delisting, the board has approved a 50-to-1 reverse stock split effective October 12, 2026. Shareholders authorized the move in June, but the decision to execute at the maximum ratio signals urgency. Delisting pressure has been mounting since April, and the company recently disclosed a going concern warning with only $15.2 million in cash. While a reverse split does not change market capitalization, it can reduce liquidity and often precedes further dilution. The split also proportionally adjusts outstanding warrants and options, preserving their economic terms.
How filings like this one have moved
In the 30 days to Oct 7, 2026, 36.1% of the 1056 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDCX was trading at $0.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.1M. The 52-week trading range was $0.14 to $2.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.